Modality
Bispecific Ab
MOA
CAR-T CD19
Target
FXIa
Pathway
Complement
Endometrial CaADHDHuntington's
Development Pipeline
Preclinical
~Aug 2015
→ ~Nov 2016
Phase 1
~Feb 2017
→ ~May 2018
Phase 2
~Aug 2018
→ ~Nov 2019
Phase 3
~Feb 2020
→ ~May 2021
NDA/BLA
Aug 2021
NDA/BLACurrent
NCT06508629
1,046 pts·Endometrial Ca
2021-08→TBD·Active
1,046 total pts1 indication
Approved
CompletedCurrentUpcoming
Trial Timeline
NDA/BLA
Active
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06508629 | NDA/BLA | Endometrial Ca | Active | 1046 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| Datoglumide | AbbVie | Approved | CFTR | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| GIL-9142 | Gilead Sciences | Phase 1 | FXIa | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 |